TherapeuticsMD
TXMD
143 hedge funds and large institutions have $791M invested in TherapeuticsMD in 2018 Q1 according to their latest regulatory filings, with 23 funds opening new positions, 52 increasing their positions, 32 reducing their positions, and 24 closing their positions.
63% more repeat investments, than reductions
Existing positions increased: 52 | Existing positions reduced: 32
0% less ownership
Funds ownership: 1.5% → 1.5% (-0%)
1% less funds holding
Funds holding: 144 → 143 (-1)
4% less first-time investments, than exits
New positions opened: 23 | Existing positions closed: 24
19% less capital invested
Capital invested by funds: $982M → $791M (-$190M)
40% less call options, than puts
Call options by funds: $1.92M | Put options by funds: $3.19M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Bank of New York Mellon
New York
|
+$18.9M |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$11.6M |
| 3 |
Axa
Paris,
France
|
+$5.96M |
| 4 |
Ameriprise
Minneapolis,
Minnesota
|
+$3.34M |
| 5 |
Renaissance Technologies
New York
|
+$1.03M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$21M |
| 2 |
NM
Newtyn Management
New York
|
-$7.55M |
| 3 |
NC
Nexthera Capital
New York
|
-$3.19M |
| 4 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
-$2.9M |
| 5 |
BlackRock
New York
|
-$2.84M |
TXMD Hedge Fund Activity: Q1 2018 in Review
143 of the 4,372 institutional investors tracked by Wall St. Rank reported a position in TherapeuticsMD (TXMD) for Q1 2018, worth a combined $791M — down 19% from $982M a quarter earlier.
Sellers outnumbered buyers: 24 funds closed out of TXMD and 23 opened new positions — a net loss of 1 holder — while 32 trimmed existing stakes and 52 added.
The largest buyer was Bank of New York Mellon, adding an estimated $18.9M. The largest seller was Fidelity Investments, cutting an estimated $21M.
- 143 institutional investors held TherapeuticsMD (TXMD) as of Q1 2018, down from 144 in Q4 2017.
- Funds reported $791M of TherapeuticsMD stock for Q1 2018, down 19% quarter-over-quarter.
- 23 funds opened new TherapeuticsMD positions in Q1 2018 and 24 closed out, a net change of -1 holder.
- The largest TherapeuticsMD buyer in Q1 2018 was Bank of New York Mellon, an estimated $18.9M added.
- The largest TherapeuticsMD seller in Q1 2018 was Fidelity Investments, an estimated $21M sold.
Based on aggregated 13F filings for Q1 2018.